Literature DB >> 24240472

Risk factors for early relapse during maintenance therapy after a single infusion of rituximab in children with steroid-dependent nephrotic syndrome.

Shuichiro Fujinaga1, Daishi Hirano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24240472     DOI： 10.1007/s00467-013-2674-6

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


× No keyword cloud information.
  3 in total

1.  Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab.

Authors:  Shuichiro Fujinaga; Tomonosuke Someya; Tsuneki Watanabe; Akira Ito; Yoshiyuki Ohtomo; Toshiaki Shimizu; Kazunari Kaneko
Journal:  Eur J Pediatr       Date:  2012-12-28       Impact factor: 3.183

2.  Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome.

Authors:  Stéphanie Tellier; Karine Brochard; Arnaud Garnier; Flavio Bandin; Brigitte Llanas; Vincent Guigonis; Mathilde Cailliez; Christine Pietrement; Olivier Dunand; Sylvie Nathanson; Aurélia Bertholet-Thomas; Lydia Ichay; Stéphane Decramer
Journal:  Pediatr Nephrol       Date:  2013-01-23       Impact factor: 3.714

3.  Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome.

Authors:  Shuichi Ito; Koichi Kamei; Masao Ogura; Mai Sato; Takuya Fujimaru; Tomoaki Ishikawa; Tomohiro Udagawa; Kazumoto Iijima
Journal:  Pediatr Nephrol       Date:  2011-05-10       Impact factor: 3.651
  3 in total
  4 in total

1.  Risk factors for early B cell recovery following single-dose rituximab therapy in Japanese children with steroid-dependent nephrotic syndrome.

Authors:  Shuichiro Fujinaga; Tomohiko Nishino
Journal:  Pediatr Nephrol       Date:  2018-09-08       Impact factor: 3.714

2.  Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.

Authors:  Shuichiro Fujinaga; Daishi Hirano; Akira Mizutani; Koji Sakuraya; Akifumi Yamada; Shunsuke Sakurai; Toshiaki Shimizu
Journal:  Clin Exp Nephrol       Date:  2016-08-24       Impact factor: 2.801

3.  Positive role of rituximab in switching from cyclosporine to mycophenolate mofetil for children with high-dose steroid-dependent nephrotic syndrome.

Authors:  Shuichiro Fujinaga; Koji Sakuraya; Akifumi Yamada; Yasuko Urushihara; Yoshiyuki Ohtomo; Toshiaki Shimizu
Journal:  Pediatr Nephrol       Date:  2015-01-10       Impact factor: 3.714

Review 4.  Nephrotic syndrome: what's new, what's hot?

Authors:  Hee Gyung Kang; Hae Il Cheong
Journal:  Korean J Pediatr       Date:  2015-08-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.